August 27, 2018 / 8:24 PM / 24 days ago

BRIEF-Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics

Aug 27 (Reuters) - Affimed NV:

* AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS

* AFFIMED NV - TO RECEIVE $96 MILLION UPFRONT AND COMMITTED FUNDING AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $5.0 BILLION INCLUDING MILESTONE PAYMENTS

* AFFIMED NV - ADDITIONAL $5.0 BILLION CO MAY RECEIVE ALSO INCLUDES ROYALTIES ON SALES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below